Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats

Clinical and Experimental Nephrology

Volumn 13, Issue 6, 2009, Pages 578-584

  Yokoo, Koji ^a   Murakami, Risa ^a   Matsuzaki, Takanobu ^a   Yoshitom, Kanako ^a   Hamada, Akinobu ^b   Saito, Hideyuki ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Acute kidney injury; Cisplatin; Hypomagnesemia; Organic cation transporter

Indexed keywords

ANTIPORTER; CATECHOLAMINE TRANSPORTER; CISPLATIN; MAGNESIUM; MATE1 PROTEIN, RAT; ORGANIC CATION TRANSPORTER; SLC22A1 PROTEIN, RAT; SLC22A2 PROTEIN, RAT;

ACUTE KIDNEY FAILURE; ANIMAL; ARTICLE; BLOOD; KIDNEY; MAGNESIUM DEFICIENCY; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT; UPREGULATION;

ANIMALS; ANTIPORTERS; CATECHOLAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; CISPLATIN; KIDNEY; KIDNEY FAILURE, ACUTE; MAGNESIUM; MAGNESIUM DEFICIENCY; MALE; ORGANIC CATION TRANSPORT PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; UP-REGULATION;

EID: 76249092211     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-009-0215-1     Document Type: Article

References (28)

1. Rozencweig M, von Hoff DD, Slavik M, Muggia FM. Cis- diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med. 1977;86:803-12.
2. Einhorn LH, Williams SD. The role of cis-platinum in solidtumor therapy. N Engl J Med. 1979;300:289-91.
3. Troy L, McFarland K, Littman-Power S, Kelly BJ, Walpole ET, Wyld D, et al. Cisplatin-based therapy: a neurological and neuropsychological review. Psychooncology. 2000;9:29-39. (Pubitemid 30110388)
4. Inui K, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 2000;58:944-58.
5. Ohta KY, Inoue K, Hayashi Y, Yuasa H. Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney. Drug Metab Dispos. 2006;34:1868-74. (Pubitemid 44771715)
6. +/organic cation antiporter MATE1. Pharm Res. 2006;23:1696-701.
7. +/ organic cation antiporters (MATE/SLC47A). Biochem Pharmacol. 2008;75:1689-96.
8. Schilsky RL, Barlock A, Ozols RF. Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep. 1982;66:1767-9. (Pubitemid 12000635)
9. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev. 1999;25:47-58. (Pubitemid 29178536)
10. Mavichak V, Wong NL, Quamme GA, Magil AB, Sutton RA, Dirks JH. Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney Int. 1985;28:914-21. (Pubitemid 16148393)
11. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334:115-24. (Pubitemid 47262919)
12. Lajer H, Kristensen M, Hansen HH, Nielsen S, Frokiaer J, Ostergaard LF, et al. Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol. 2005; 56:535-42. (Pubitemid 41549156)
13. Matsuzaki T, Morisaki T, Sugimoto W, Yokoo K, Sato D, Nonoguchi H, et al. Altered pharmacokinetics of cationic drugs caused by down-regulation of renal rat organic cation transporter 2 (Slc22a2) and rat multidrug and toxin extrusion 1 (Slc47a1) in ischemia/reperfusion-induced acute kidney injury. Drug Metab Dispos. 2008;36:649-54. (Pubitemid 351468369)
14. Weglicki WB, Phillips TM, Freedman AM, Cassidy MM, Dickens BF. Magnesium-deficiency elevates circulating levels of inflammatory cytokines and endothelin. Mol Cell Biochem. 1992; 110:169-73.
15. Malpuech-Brugere C, Nowacki W, Daveau M, Gueux E, Linard C, Rock E, et al. Inflammatory response following acute magnesium deficiency in the rat. Biochim Biophys Acta. 2000; 1501:91-8. (Pubitemid 30323647)
16. Chaudhary DP, Boparai RK, Bansal DD. Implications of oxidative stress in high sucrose low magnesium diet fed rats. Eur J Nutr. 2007;46:383-90. (Pubitemid 350276233)
17. Asai T, Nakatani T, Yamanaka S, Tamada S, Kishimoto T, Tashiro K, et al. Magnesium supplementation prevents experimental chronic cyclosporine a nephrotoxicity via renin-angiotensin system independent mechanism. Transplantation. 2002;74:784-91.
18. Yonezawa A, Masuda S, Nishihara K, Yano I, Katsura T, Inui K. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol. 2005;70:1823-31. (Pubitemid 41612013)
19. Asaka J, Terada T, Okuda M, Katsura T, Inui K. Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3. Pharm Res. 2006; 23:697-704.
20. 2+. J Biol Chem. 1985; 260:8683-9.
21. Tong GM, Rude RK. Magnesium deficiency in critical illness. J Intensive Care Med. 2005;20:3-17. (Pubitemid 43093904)
22. Matsuzaki T, Watanabe H, Yoshitome K, Morisaki T, Hamada A, Nonoguchi H, et al. Downregulation of organic anion transporters in rat kidney under ischemia/reperfusion-induced acute renal failure. Kidney Int. 2007;71:539-47. (Pubitemid 46398686)
23. Morisaki T, Matsuzaki T, Yokoo K, Kusumoto M, Iwata K, Hamada A, et al. Regulation of renal organic ion transporters in cisplatin-induced acute kidney injury and uremia in rats. Pharm Res. 2008;25:2526-33.
24. Ji L, Masuda S, Saito H, Inui K. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int. 2002;62:514-24. (Pubitemid 34779762)
25. Masubuchi Y, Kawasaki M, Horie T. Down-regulation of hepatic cytochrome P450 enzymes associated with cisplatin-induced acute renal failure in male rats. Arch Toxicol. 2006;80:347-53. (Pubitemid 43725218)
26. Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol. 2007;74:477-87. (Pubitemid 46963232)
27. Lin X, Okuda T, Holzer A, Howell SB. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol. 2002;62:1154-9. (Pubitemid 35222507)
28. Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2009; 296:F505-11.